Ignite Creation Date:
2025-12-25 @ 2:01 AM
Ignite Modification Date:
2025-12-27 @ 11:57 AM
Study NCT ID:
NCT06749860
Status:
RECRUITING
Last Update Posted:
2024-12-27
First Post:
2024-12-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-02-02
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06-06
Completion Date Type:
ESTIMATED
First Submit Date:
2024-12-12
First Submit QC Date:
None
Study First Post Date:
2024-12-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-19
Last Update Post Date:
2024-12-27
Last Update Post Date Type:
ACTUAL